Adam W.
- Country
- Poland
- Department
- not applicable
Research Overview
- A Randomized, Double-masked Study Comparing the Efficacy and Safety of AVT29 Versus High-Dose Aflibercept in Participants with Diabetic Macular Edema
- Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia
- Evaluation of Efficacy and Safety of Intravitreal EYE103 Versus Ranibizumab in Diabetic Macular Edema: A Randomized, Double-Masked, Multi-Center Study
Data & Insights
Has run more than one trial at 77 of 162 partner sites.
Specializations
Corneal Healing and Neurotrophic Disorders
The investigator focuses on conditions affecting corneal integrity and nerve function, such as Neurotrophic Keratopathy and persistent epithelial defects.
- Neurotrophic Keratopathy
- Persistent Corneal Epithelial Defect
- Cenegermin therapy
- RGN-259
Research aims to restore corneal surface health through targeted biologics.
Retinal Vascular and Edema Conditions
Work includes retinal vascular complications, notably Diabetic Macular Edema and macular oedema secondary to retinal vein occlusion.
- Diabetic Macular Edema
- Macular Oedema Secondary to Retinal Vein Occlusion
- Uveitic Macular Edema
- AVT29 comparative studies
Therapeutic strategies target fluid accumulation and vascular leakage.
Age‑Related and Myopic Neovascularization
Investigations address neovascular growth in aging and myopic eyes, including Neovascular Age‑Related Macular Degeneration.
- Neovascular Age‑Related Macular Degeneration
- Myopic Choroidal Neovascularization
- Choroidal neovascularization secondary to pathologic myopia
- Faricimab efficacy
Efforts explore anti‑angiogenic agents and sustained‑release platforms.
Ocular Surface and Eyelid Disorders
The clinician also studies eyelid function and ocular surface disease such as Acquired Blepharoptosis.
- Acquired Blepharoptosis
- Oxymetazoline eye drops
- Lid repositioning pharmacotherapy
- Blink mechanics
Therapies aim to improve visual field and comfort.
Innovative Intravitreal Delivery Systems
A key interest lies in advanced administration technologies like the Port Delivery System for sustained drug release.
- Port Delivery System with Ranibizumab
- Pre‑filled syringe (PFS) usability
- Intravitreal faricimab
- SB11 PFS preparation
Delivery innovations seek to reduce injection frequency and enhance patient adherence.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.